Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Oslo Bors  >  Photocure ASA    PHO   NO0010000045

Delayed Quote. Delayed  - 09/26 10:28:09 am
40 NOK   -3.85%
09/13 PHOTOCURE ASA : Share capital increase registered
09/12 PHOTOCURE : Data published in World Journal of Urology show that Blu..
09/06 PHOTOCURE ASA : Update on management shareholdings and exercise of e..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Photocure ASA : Mandatory notification of trade

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/22/2013 | 11:02am CEST
Photocure ASA - Selling price of shares

Reference is made to the statement dated 15.03.2013. The payment has been determined based on a selling price of NOK 40.2584 per share.

After exercising options, Grete Hogstad holds 8 750 unexercised options in the Company, corresponding to 8 750 shares at the strike price of NOK 20.30. In addition she holds; 7
200 unexercised options, corresponding to 7 200 shares at the strike price of NOK 32.00;
23 400 unexercised options, corresponding to 23 400 shares at the strike price of NOK
44.00; and 17 250 unexercised options, corresponding to 17 250 shares at the strike price of NOK 50.75. After completion of the abovementioned transactions, the primary insider holds 10 500 shares in the Company.
After exercising options, Gry Stensrud holds 6 250 unexercised options in the Company, corresponding to 6 250 shares at the strike price of 20.30. In addition she holds; 19 050 unexercised options, corresponding to 19 050 shares at the strike price of NOK 44.00; and 22 500 unexercised options, corresponding to 22 500 shares at the strike price of NOK 50.75. After completion of the abovementioned transactions, the primary insider holds 6 shares in the Company.

For further information, please contact: Photocure

CFO Erik Dahl
Tel: +47 450 55 000, Email: ed@photocure.no

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PHOTOCURE ASA
09/13 PHOTOCURE ASA : Share capital increase registered
09/12 PHOTOCURE : Data published in World Journal of Urology show that Blue Light Cyst..
09/06 PHOTOCURE ASA : Update on management shareholdings and exercise of employee shar..
08/29 PHOTOCURE : Hosts Bladder Cancer Key Opinion Leader Breakfast in New York City
08/24 PHOTOCURE : Hexvix« marketing authorization approval in Australia
08/23 PHOTOCURE : Results for second quarter and first half year 2016
08/23 PHOTOCURE : Presentation of the second quarter 2016 results and Hexvix/Cysview u..
08/23 PHOTOCURE ASA : Results for second quarter and first half year 2016
08/18PHOTOCURE ASA : half-yearly earnings release
08/17 PHOTOCURE ASA : Presentation of the second quarter 2016 results and Hexvix/Cysvi..
More news
Sector news : Pharmaceuticals - NEC
07:49aDJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/23 Endo International CEO steps down, Campanelli named successor
More sector news : Pharmaceuticals - NEC
Advertisement
Financials ( NOK)
Sales 2016 135 M
EBIT 2016 -22,5 M
Net income 2016 -3,47 M
Debt 2016 103 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 7,39x
EV / Sales 2017 6,18x
Capitalization 896 M
More Financials
Chart PHOTOCURE ASA
Duration : Period :
Photocure ASA Technical Analysis Chart | PHO | NO0010000045 | 4-Traders
Full-screen chart
Technical analysis trends PHOTOCURE ASA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 50,0  NOK
Spread / Average Target 20%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kjetil Hestdal President, Chief Executive Officer & Media Contact
Bente-Lill Bjerkelund Rom°ren Chairman
Erik Dahl Chief Financial Officer & IR Contact
Inger Ferner Heglund Vice President-Research & Development
Xavier Denis Yon Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PHOTOCURE ASA-1.43%110
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.18%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.6.13%207 809
MERCK & CO., INC.19.20%174 098
More Results